Jennison Associates LLC Ironwood Pharmaceuticals Inc Transaction History

Jennison Associates LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 31, 2023	BUY	$8.25 - $11.35 $587,730 - $808,574	71,240 New	71,240 $686,000
Q2 2022 Aug 02, 2022	SELL	$11.05 - $12.72 $744,736 - $857,289	-67,397 Reduced 50.19%	66,879 $771,000
Q1 2022 May 11, 2022	BUY	$10.61 - $12.88 $94,948 - $115,263	8,949 Added 7.14%	134,276 $1.69 Million
Q4 2021 Feb 08, 2022	SELL	$10.86 - $13.95 $557,443 - $716,053	-51,330 Reduced 29.06%	125,327 $1.46 Million
Q3 2021 Nov 09, 2021	BUY	$11.92 - $13.92 $727,525 - $849,593	61,034 Added 52.79%	176,657 $2.31 Million
Q2 2021 Aug 12, 2021	BUY	$10.16 - $13.11 $94,904 - $122,460	9,341 Added 8.79%	115,623 $1.49 Million
Q1 2021 May 11, 2021	SELL	$9.04 - $11.86 $41,330 - $54,223	-4,572 Reduced 4.12%	106,282 $1.19 Million
Q4 2020 Feb 05, 2021	SELL	$9.05 - $12.2 $730,769 - $985,125	-80,748 Reduced 42.14%	110,854 $1.26 Million
Q3 2020 Nov 04, 2020	BUY	$8.99 - $10.74 $1.72 Million - $2.06 Million	191,602 New	191,602 $1.72 Million

238

162M

11.2M

9.1K

Ticker IRWD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 153,231,008
Market Cap $541M
Description
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...

Get notified when there are updates to the investment portfolio of Jennison Associates LLC, based on Form 13F filings with the SEC.

Stay updated on Jennison Associates LLC with notifications on news.